Abstract
Over the past decade, CAR-T cells have emerged as one of the most powerful cellular immune therapy approaches in the battle against haematological malignancies. Nonetheless, similar to other immunotherapeutic approaches, tumour cells develop strategies to evade CAR-T cell therapy, often with the support of a highly immunosuppressive and protective tumour microenvironment. To date, antigen loss, immune dysfunction, exhaustion and (microenvironment-mediated) upregulation of antiapoptotic pathways have been identified as major modes of tumour escape from CAR-T cell therapy. This chapter will focus on our current understanding of these modes of immune escape from CAR-T cells.
You have full access to this open access chapter, Download chapter PDF
Similar content being viewed by others
Over the past decade, CAR-T cells have emerged as one of the most powerful cellular immune therapy approaches in the battle against haematological malignancies. Nonetheless, similar to other immunotherapeutic approaches, tumour cells develop strategies to evade CAR-T cell therapy, often with the support of a highly immunosuppressive and protective tumour microenvironment. To date, antigen loss, immune dysfunction, exhaustion and (microenvironment-mediated) upregulation of antiapoptotic pathways have been identified as major modes of tumour escape from CAR-T cell therapy. This chapter will focus on our current understanding of these modes of immune escape from CAR-T cells.
Immune Escape and CAR-T Cell Resistance Related to Antigen Loss
Antigen loss represents the ultimate adaptation of a cancer cell to the selective pressure of targeted immunotherapy. While antigen downregulation or dim expression is a well-known event in lymphoma and myeloma treated with therapeutic IgG antibodies (Plesner et al. 2020; Jilani et al. 2003), complete target loss is a phenomenon typically occurring after T-cell-based therapy, such as CAR-T cell or T cell engaging bispecific antibodies (TCE) therapy, and rarely after treatment with antibody-drug conjugates (ADCs).
In B cell malignancies, CD19 loss has been noted in up to 40% of patients with B cell acute lymphoblastic leukaemia treated with different CAR 19 products (Orlando et al. 2018). Point mutations in CD19 have been described to lead to nonfunctional anchoring of the CD19 protein to the cell membrane and consequently to a loss of surface antigen (Orlando et al. 2018). Deleterious mutations and alternatively spliced CD19 mRNA variants were identified in two other studies (Asnani et al. 2020; Sotillo et al. 2015). In B-ALL with rearrangement of the mixed lineage leukaemia (MLL) gene, some patients relapsed with clonally related acute myeloid leukaemia after treatment with CD19 CAR-T cells, adding a switch to a CD19-negative myeloid phenotype as another mechanism of resistance (Gardner et al. 2016). In DLBCL, the frequency of CD19 loss after CAR19 axicabtagene ciloleucel (axi-cel) treatment was 33% (Neelapu et al. 2017; Neelapu et al. 2019), and alternatively spliced CD19 mRNA species could be identified. In follicular lymphoma and DLBCL treated with CD20 X CD3 bispecific TCE, CD20 loss relapses were seen, but the frequency is yet to be reported (Bannerji et al. 2018). Furthermore, a single case of CD22 loss was described after ADC inotuzumab-ozogamicin treatment in a paediatric patient with B-ALL (Paul et al. 2019). Taken together, antigen loss is a key mechanism of resistance to novel immunotherapies targeting CD19, CD20, and CD22. In myeloma, downregulation of BCMA was recorded in a significant proportion of patients following BCMA CAR-T therapy, but intensity increased back towards baseline in almost all patients (Cohen et al. 2019). However, three case reports described irreversible BCMA loss after anti-BCMA CAR-T cell treatment (Da Via et al. 2021; Samur et al. 2020; Leblay et al. 2020). In two of these cases, homozygous BCMA gene deletions were identified as the biological underpinning of antigen loss. In the third case, the authors found a heterozygous BCMA deletion together with a BCMA mutation, leading to antigen loss. In summary, biallelic events impacting the BCMA locus represent one molecular mechanism of antigen loss after BCMA CAR-T therapy. However, these events seem to be rare. In the KarMMa trial, only 4% of patients relapsed without an increase in soluble BCMA, which is thought to be a biomarker of this type of resistance (Munshi et al. 2021). Heterozygous BCMA deletions, present in approximately 7% of anti-BCMA naïve patients, represent a risk factor for BCMA loss-relapse after T-cell-based therapy (Da Via et al. 2021). While a plethora of alternative antigens, such as FCRH5 or GPRC5D, are currently being investigated in early clinical trials (Rasche et al. 2020), antigen loss for these targets has not been reported thus far. However, MM is a disease associated with high frequencies of copy number aberrations, including deletions impacting genes encoding immunotherapy targets, and we expect biallelic events leading to antigen loss to also be relevant for MM targets other than BCMA. Multispecific CAR-T cells or combinations of monospecific targeted immunotherapies may overcome antigen loss in future trials (Fernández de Larrea et al. 2020).
Immune Dysfunction and Exhaustion of CAR-T Cells
In addition to antigen loss, a number of other mechanisms also limit or abrogate the effective recognition of cancer cells by CAR-T cells, either directly conveyed by tumour cells or through rewiring of the microenvironment. In preclinical models, especially in solid tumours, it was shown that tumour-infiltrating CAR-T cells undergo rapid loss of functionality, limiting their therapeutic efficacy. This hyporesponsiveness appears to be reversible when the T cells are isolated away from the tumour and is associated with upregulation of intrinsic T cell inhibitory enzymes (diacylglycerol kinase and SHP-1) and with the expression of surface inhibitory receptors (PD1, LAG3, TIM3, and 2B4) (Moon et al. 2014).
Additionally, in patients with diffuse large B cell lymphoma (DLBCL) treated with axicabtagene ciloleucel (axi-cel), it has been shown that tumour-infiltrating CAR-T cells express the inhibitory receptor PD1 and that they represent only a minor fraction of the immune cells detectable in the tumour (Chen et al. 2020). Of note, immunogenic chemotherapy can enhance the recruitment of CAR-T cells to the tumour bed by inducing the release of chemokines from monocytes, and this can potently synergize with immune checkpoint blockade (Srivastava et al. 2021). In another recent study in DLCBL, interferon (IFN) signalling expression, along with high blood levels of monocytic myeloid-derived suppressor cells (M-MDSCs), IL-6 and ferritin, was associated with a lack of a durable response to axi-cel. The authors showed that high IFN signalling is associated with the expression of multiple checkpoint ligands, including PD-L1, on lymphoma cells and that these levels were higher in patients who lacked a durable response to CAR-T therapy (Jain et al. 2021). However, impairment of IFN signalling, such as through mutations or downmodulation of JAK2 and other pathway components, can confer tumour cell resistance to killing by CAR-redirected T cells (Arenas et al. 2021).
These findings have direct implications for the design of next-generation CAR-T cell protocols: a number of strategies are now being explored to combine immune checkpoint blockade with CAR-T cell therapy, either by coinfusion of genetically modified lymphocytes with monoclonal antibodies or by engineering the cell to produce the relevant scFv (Carneiro and El-Deiry 2020), be resistant to inhibitory signals (Cullen et al. 2010), or even transform signals under activating stimuli (Sutton et al. 2000). Moreover, novel promising compounds have been shown to counteract the activity of T cell inhibitory enzymes (Moon et al. 2014).
Microenvironment-Mediated Tumour Resistance to CAR-T Cells
Immune suppression or exhaustion is not the only mechanism by which tumour cells can become less susceptible to CAR-T cell-mediated cytotoxicity. In many haematological cancers, the bone marrow tumour microenvironment (BMME) is known to upregulate antiapoptotic mechanisms in tumour cells through tight cross-talk of mesenchymal stromal cells (MSCs) and tumour cells. Remarkably, tumour cell lysis by T and NK cells is also largely mediated via activation of extrinsic and intrinsic apoptosis pathways (Hanabuchi et al. 1994; Falschlehner et al. 2009; Carneiro and El-Deiry 2020; Cullen et al. 2010; Sutton et al. 2000). Thus, the idea that BMMSCs might also induce resistance to T and MK cell-mediated cytotoxic activity through upregulation of antiapoptotic mechanisms has recently been tested, and the results showed that MM cell-BMMSC interactions can indeed protect MM cells from conventional cytotoxic T cells and from (daratumumab redirected) NK cells (McMillin et al. 2012; de Haart et al. 2013; de Haart et al. 2016). These studies were recently extended to CAR-T cells by testing a panel of nine different MM-reactive CAR-T cells that were reactive to three different MM-associated antigens (CD138, BCMA, and CD38) with different target affinities and with different costimulatory domains (CD28, 4-1BB, or CD28 plus 4-1BB) (Holthof et al. 2021a). In the absence of BMMSCs, BCMAbb2121 CAR-T cells, high affinity CD38 CAR-T cells, and intermediate affinity CD38 CAR-T cells containing CD28 costimulatory domains showed high levels of anti-MM cell lysis, whereas other CAR-T cells showed moderate cytotoxic activity against MM cells. BMMSCs did not modulate the lytic activity of highly lytic CAR-T cells but readily protected MM cells against all other CAR-T cells with intermediate killing capacity. Overall, a strong inverse correlation was demonstrated between the lytic capacity of the CAR-T cells and the extent of BMMSC-mediated protection. Furthermore, the BMMSC-mediated protection of MM cells from these CAR-T cells was readily abrogated by inhibition of survivin, MCL-1, and Xiap using the small molecule FL118. Thus, the results confirmed that BMMSC-mediated immune resistance was mediated by negative regulation of apoptotic pathways. In addition, the importance of the tumour stroma in the efficacy of CAR-T cells has also been suggested in a solid tumour mouse model, where destruction of the tumour stroma contributed to eradication of large tumours by HER2-specific CAR-T cells (Textor et al. 2014). Based on these studies, overcoming BMMSC-mediated immune resistance seems possible by increasing the overall avidity and killing activity of CAR-T cells. This may be achieved by designing CARs containing high affinity antigen recognition domains, tandem CARs, or dual CAR strategies (van der Schans et al. 2020). Alternatively, using the CD28 costimulatory domain (Drent et al. 2019; Drent et al. 2017) or engineering CAR-T cells with cytotoxic effector molecules can upregulate CAR-T cell activity. Indeed, it has recently been demonstrated that BMSMSC-mediated immune resistance towards the NK cell line KHYG-1 can be abrogated by engineering it with a CD38 CAR and/or with a DR5-specific, optimized TRAIL variant (Holthof et al. 2021b). CAR-T cells may also be equipped with caspase-independent apoptotic molecules, such as granzyme-A (Borner and Monney 1999).
In addition, a number of earlier and recent studies indicate the importance of apoptotic pathways for the efficacy of other CAR-T cells. For instance, CD19 CAR-T cells were previously found to benefit from combination with the BCL-2 inhibitor ABT-737 (Karlsson et al. 2013). Recently, similar results were observed when third-generation CD19 CAR-T cells were combined with another BCL-2 inhibitor, ABT199 (Yang et al. 2019). Finally, two independent loss-of-function screens in ALL cell lines identified impaired death receptor pathways as another mechanism of resistance to CD19-targeted CAR therapy. Loss of FADD, BID, and tumour necrosis factor-related apoptosis-inducing ligand 2 (TRAIL2) in leukaemia cells was shown to render them more resistant to cytotoxicity and to drive T cell exhaustion upon prolonged stimulation (Singh et al. 2020; Dufva et al. 2020). The combination of CAR-T cells with the SMAC mimetic compound birinapant significantly improved the lysis of malignant cells (Dufva et al. 2020). Thus, when increasing the lytic capacity of CAR-T cells is not possible or desirable, especially if the target antigen is not entirely tumour-specific, tumour cells can be made more sensitive by combining CAR-T cells with small molecules targeting regulatory proteins in the intrinsic and extrinsic apoptotic pathways, as shown in these studies.
Key Points
-
1.
Loss of expression of the target antigen on tumour cells via the selective immune pressure of CAR-T cells is a major mechanism of CAR-T cell therapy failure.
-
2.
T cell exhaustion of CAR-T cells can decrease their function.
-
3.
Multiple other cells in the tumour microenvironment can contribute to inhibition of CAR-T cell function.
References
Arenas EJ, Martínez-Sabadell A, Rius Ruiz I, Román Alonso M, Escorihuela M, Luque A, et al. Acquired cancer cell resistance to T cell bispecific antibodies and CAR-T targeting HER2 through JAK2 down-modulation. Nature. Communications. 2021;12(1):1237.
Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. 2020;34:1202–7.
Bannerji R, Arnason JE, Advani R, Brown JR, Allan JN, Ansell SM, et al. Emerging clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and other B-cell non-Hodgkin lymphoma (B-NHL) subtypes. Blood. 2018;132(Suppl 1):1690.
Borner C, Monney L. Apoptosis without caspases: an inefficient molecular guillotine? Cell Death Differ. 1999;6(6):497–507.
Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395–417.
Chen P-H, Lipschitz M, Weirather JL, Jacobson C, Armand P, Wright K, et al. Activation of CAR and non-CAR-T cells within the tumor microenvironment following CAR-T cell therapy. JCI Insight. 2020;5(12):e134612.
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR-T cells are clinically active in multiple myeloma. J Clin Invest. 2019;129(6):2210–21.
Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010;17(4):616–23.
Da Via MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR-T cells in a patient with multiple myeloma. Nat Med. 2021;27:616–9.
Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther. 2017;25(8):1946–58.
Drent E, Poels R, Ruiter R, van de Donk N, Zweegman S, Yuan H, et al. Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells. Clin Cancer Res. 2019;25(13):4014–25.
Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR-T cell cytotoxicity. Blood. 2020;135(9):597–609.
Falschlehner C, Schaefer U, Walczak H. Following TRAIL’s path in the immune system. Immunology. 2009;127(2):145–54.
Fernández de Larrea C, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, et al. Defining an optimal dual-targeted CAR-T cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape–driven relapse in multiple myeloma. Blood Cancer Discovery. 2020;1(2):146–54.
Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T cell therapy. Blood. 2016;127(20):2406–10.
de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, et al. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance. Clin Cancer Res. 2013;19(20):5591–601.
de Haart SJ, Holthof L, Noort WA, Minnema MC, Emmelot ME, Aarts-Riemens T, et al. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. Haematologica. 2016;101(8):e339–42.
Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, Nishimura Y, et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci. 1994;91(11):4930–4.
Holthof L, van der Schans J, Katsarau A, Poels R, Gelderloos A, van Hal SE, et al. Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR-T cells through inhibition of apoptosis. Clin Cancer Res. 2021a;27(13):3793–803.
Holthof L, van der Horst HJ, Gelderloos A, Poels R, Li F, Groen R, et al. Bone marrow mesenchymal stromal cell-mediated resistance in multiple myeloma against NK cells can be overcome by introduction of CD38-CAR or TRAIL-variant. Hema. 2021b;5(5):e561.
Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells associate with CAR-T cell failure in large B cell lymphoma. Blood. 2021;137(19):2621–33.
Jilani I, O’Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102(10):3514–20.
Karlsson SCH, Lindqvist AC, Fransson M, Paul-Wetterberg G, Nilsson B, Essand M, et al. Combining CAR-T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Cancer Gene Ther. 2013;20(7):386–93.
Leblay N, Maity R, Barakat E, McCulloch S, Duggan P, Jimenez-Zepeda V, et al. Cite-Seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy. Blood. 2020;136(Suppl 1):11–2.
McMillin DW, Delmore J, Negri JM, Vanneman M, Koyama S, Schlossman RL, et al. Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012;119(15):e131–8.
Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res. 2014;20(16):4262–73.
Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR-T cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.
Neelapu SS, Rossi JM, Jacobson CA, Locke FL, Miklos DB, Reagan PM, et al. CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel. Blood. 2019;134(Suppl 1):203.
Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–6.
Paul MR, Wong V, Aristizabal P, Kuo DJ. Treatment of recurrent refractory pediatric pre-B acute lymphoblastic leukemia using Inotuzumab Ozogamicin monotherapy resulting in CD22 antigen expression loss as a mechanism of therapy resistance. J Pediatr Hematol Oncol. 2019;41(8):e546–e9.
Plesner T, van de Donk N, Richardson PG. Controversy in the use of CD38 antibody for treatment of myeloma: is high CD38 expression good or bad? Cell. 2020;9(2):378.
Rasche L, Hudecek M, Einsele H. What is the future of immunotherapy in multiple myeloma? Blood. 2020;136(22):2491–7.
Samur MK, Fulciniti M Aktas-Samur A, Hamid Bazarbachi A, Tai Y, Campbell TB, Petrocca F, Hege K, Kaiser S, Anderson K, Munshi NC (2020) Biallelic loss of BCMA triggers resistance to anti-BCMA CAR-T cell therapy in multiple myeloma (abstract #721). 62nd ASH annual meeting and exposition
van der Schans JJ, van de Donk N, Mutis T. Dual targeting to overcome current challenges in multiple myeloma CAR-T cell treatment. Front Oncol. 2020;10:1362.
Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR-T cell dysfunction. 2020;10(4):552–67.
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282–95.
Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell. 2021;39(2):193–208.e10.
Sutton VR, Davis JE, Cancilla M, Johnstone RW, Ruefli AA, Sedelies K, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med. 2000;192(10):1403–14.
Textor A, Listopad JJ, Wuhrmann LL, Perez C, Kruschinski A, Chmielewski M, et al. Efficacy of CAR-T cell therapy in large tumors relies upon stromal targeting by IFNgamma. Cancer Res. 2014;74(23):6796–805.
Yang M, Wang L, Ni M, Schubert M-L, Neuber B, Hückelhoven-Krauss A, et al. The effect of apoptosis inhibitor blockade agents on the third generation CD19 CAR-T cells. Blood. 2019;134(Suppl 1):5620.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Copyright information
© 2022 The Author(s)
About this chapter
Cite this chapter
Rasche, L., Vago, L., Mutis, T. (2022). Tumour Escape from CAR-T Cells. In: Kröger, N., Gribben, J., Chabannon, C., Yakoub-Agha, I., Einsele, H. (eds) The EBMT/EHA CAR-T Cell Handbook. Springer, Cham. https://doi.org/10.1007/978-3-030-94353-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-94353-0_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-94352-3
Online ISBN: 978-3-030-94353-0
eBook Packages: MedicineMedicine (R0)